Form 8-K Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 28, 2011  

HARVARD BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)


Delaware 		 
001-33957 		 
04-3306140
(State or other jurisdiction
of incorporation) 		  (Commission File Number)   (IRS Employer Identification No.)


 
84 October Hill Road, Holliston, MA 		 
01746 		 
  (Address of principal executive offices)   (Zip Code)  

Registrant's telephone number, including area code:   (508) 893-8999



________________________________________________________________________________
(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    [    ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    [    ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    [    ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    [    ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On April 28, 2011, Harvard Bioscience, Inc., (the "Company") issued a press release announcing financial results for the three months ended March 31, 2011 and thereafter held a public telephone conference call to discuss the financial results and related matters. The press release and the transcript of the conference call are furnished herewith as Exhibit 99.1 and Exhibit 99.2 respectively, and are incorporated herein by reference. The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number		 Title

99.1 Press release of Harvard Bioscience, Inc. issued on April 28, 2011.
99.2 Transcript of Harvard Bioscience, Inc. earnings release conference call held on April 28, 2011.

SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    HARVARD BIOSCIENCE, INC.
(Registrant)
April 29, 2011
(Date) 		  /s/   THOMAS MCNAUGHTON
Thomas McNaughton
Chief Financial Officer & Principal Accounting Officer